Opigolix - Astellas Pharma

Drug Profile

Opigolix - Astellas Pharma

Alternative Names: ASP-1707

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis; Rheumatoid arthritis
  • No development reported Prostate cancer

Most Recent Events

  • 25 Oct 2017 Astellas Pharma completes a phase IIa trial for Rheumatoid arthritis in Japan (PO) (NCT02884635)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Sep 2016 Phase-II clinical trials in Rheumatoid arthritis in Japan (PO) (NCT02884635)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top